DOM-GABAPENTIN 100 MG — DIN 02243743
GABAPENTIN : 100 MG · DOMINION PHARMACAL · CAPSULE · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is DOM-GABAPENTIN?
DOM-GABAPENTIN 100 MG contains GABAPENTIN : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02243743, held by DOMINION PHARMACAL, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 09-May-2025. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is DOM-GABAPENTIN used for?
Adjunctive therapy for the management of patients with epilepsy who are not satisfactorily controlled by conventional therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Gabapentin cost around the world?
Gabapentin is listed on 16 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 6 | 261 | USD███.██ |
| Australia | ex-manufacturer | 13 | 54 | AUD███.██ |
| Italy | prezzo al pubblico (classe A) | 6 | 46 | EUR███.██ |
| Czechia | max producer price (ex-factory) | 7 | 45 | CZK███.██ |
| Saudi Arabia | public | 19 | 33 | SAR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 25 | 27 | EUR███.██ |
| South Africa | single exit price | 26 | 26 | ZAR███.██ |
| Hungary | producer price (ex-factory) | 13 | 18 | HUF███.██ |
| Iceland | max wholesale | 7 | 16 | ISK███.██ |
| Romania | max producer price | 15 | 15 | RON███.██ |
| Norway | max AUP (pharmacy retail) | 4 | 14 | NOK███.██ |
| Greece | producer price (ex-factory) | 9 | 9 | EUR███.██ |
| United Arab Emirates | public | 8 | 8 | AED███.██ |
| United Kingdom | hospital | 6 | 6 | GBP███.██ |
| Luxembourg | reimbursement | 5 | 5 | EUR███.██ |
| Bahrain | retail (max) | 3 | 4 | BHD███.██ |
587 pack listings across 172 brand entries and 14 price bases, refreshed 10 Sep 2026. Ranges span every Gabapentin pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Gabapentin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
36 holders have a Canadian DIN containing Gabapentin, across 161 DINs, of which 60 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| APOTEX INC | 12 | 5 | APO-GABAPENTIN, APO-GABAPENTIN TABLETS, GABAPENTIN | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 10 | 5 | GABAPENTIN, JAMP GABAPENTIN CAPSULES, JAMP-GABAPENTIN, JAMP-GABAPENTIN TABLETS | Sourceable in Canada |
| TEVA CANADA LIMITED | 10 | 5 | GABAPENTIN, NTP-GABAPENTIN, TEVA-GABAPENTIN | Sourceable in Canada |
| ACCORD HEALTHCARE INC | 5 | 5 | GABAPENTIN CAPSULES USP, GABAPENTIN TABLETS USP | Sourceable in Canada |
| AURO PHARMA INC | 5 | 5 | AURO-GABAPENTIN, AURO-GABAPENTIN TABLETS | Sourceable in Canada |
| BGP PHARMA ULC | 5 | 5 | NEURONTIN | Sourceable in Canada |
| LABORATOIRE RIVA INC. | 5 | 5 | RIVA-GABAPENTIN | Sourceable in Canada |
| PRO DOC LIMITEE | 5 | 5 | PRO-GABAPENTIN | Sourceable in Canada |
| SIVEM PHARMACEUTICALS ULC | 5 | 5 | GABAPENTIN | Sourceable in Canada |
| SANIS HEALTH INC | 5 | 4 | GABAPENTIN | Sourceable in Canada |
| PHARMASCIENCE INC | 5 | 3 | PMS-GABAPENTIN | Sourceable in Canada |
| MINT PHARMACEUTICALS INC | 3 | 3 | MINT-GABAPENTIN | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 100 MG |
|---|---|
| Dosage form | CAPSULE |
| Route | ORAL |
| Pack configuration (monograph) | Not explicitly detailed in the provided text (mentions bottles/blisters in standard practice, but text only lists strengths and forms). |
| Storage | Not specified in the provided text (typically 15-30°C for this product). |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Gabapentin |
|---|---|
| ATC code | N02BF01 |
| AHFS class | 28:12.92 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02243743 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2243743 |
| Brand name | DOM-GABAPENTIN |
| Generic / active ingredient | GABAPENTIN : 100 MG |
| Market authorization holder | DOMINION PHARMACAL |
| Health Canada schedule | Prescription |
| ATC code | N02BF01 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N02BF |
| Current status | CANCELLED POST MARKET |
| Status date | 09-May-2025 |
| Original market date | 2002-03-11 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adjunctive therapy in adults. Gradual withdrawal over at least 1 week is recommended. Dosage adjustment required in patients with renal impairment.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to the drug or to any of the components of the formulation.
Warnings and precautions
Risk of respiratory depression, CNS depression, suicidal ideation, serious dermatological reactions (SJS/DRESS), anaphylaxis, and withdrawal seizures if abruptly discontinued.
Is Gabapentin in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by SANIS HEALTH INC, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
60 of 161 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-GABAPENTIN | 300 MG | CAPSULE | APOTEX INC | MARKETED | 02244305 |
| APO-GABAPENTIN | 800 MG | TABLET | APOTEX INC | MARKETED | 02293366 |
| APO-GABAPENTIN | 400 MG | CAPSULE | APOTEX INC | MARKETED | 02244306 |
| APO-GABAPENTIN | 600 MG | TABLET | APOTEX INC | MARKETED | 02293358 |
| APO-GABAPENTIN | 100 MG | CAPSULE | APOTEX INC | MARKETED | 02244304 |
| AURO-GABAPENTIN | 100 MG | CAPSULE | AURO PHARMA INC | MARKETED | 02321203 |
| AURO-GABAPENTIN | 400 MG | CAPSULE | AURO PHARMA INC | MARKETED | 02321238 |
| AURO-GABAPENTIN | 300 MG | CAPSULE | AURO PHARMA INC | MARKETED | 02321211 |
| AURO-GABAPENTIN TABLETS | 600 MG | TABLET | AURO PHARMA INC | MARKETED | 02428334 |
| AURO-GABAPENTIN TABLETS | 800 MG | TABLET | AURO PHARMA INC | MARKETED | 02428342 |
2 · Same class — other molecules in ATC N02BF
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Pregabalin | ACH-PREGABALIN · ACT PREGABALIN · AG-PREGABALIN · APO-PREGABALIN · +35 more | 271 | 108 | Yes |
| Gabapentin | ACT GABAPENTIN · AG-GABAPENTIN · APO-GABAPENTIN · APO-GABAPENTIN TABLETS · +35 more | 161 | 60 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N02B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N02BE | Acetaminophen (Paracetamol) · Acetaminophen, Comb Excl Psycholeptics | 1156 | 208 |
| N02BA | Acetylsalicylic Acid · Acetylsalicylic Acid, Comb Excl Psycholeptics · Acetylsalicylic Acid, Comb With Psycholeptics · Choline Salicylate, Comb. Excl Psycholeptics · Diflunisal · +3 more | 240 | 20 |
| N02BG | Cannabinoids · Floctafenine · Methoxyflurane | 7 | 3 |
| N02BB | Phenazone, Combinations Excl Psycholeptics | 2 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is DOM-GABAPENTIN called?
The same molecule, Gabapentin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Neurontin | Latin | Australia, Bahrain, Czechia, Iceland, Norway, Saudi Arabia |
| Gabapentin Teva | Latin | Czechia, Iceland, Norway |
| GAPENTIN | Latin | Australia, Saudi Arabia |
| APX-Gabapentin | Latin | Australia |
| Gabacor | Latin | Australia |
| GABANOX | Latin | Czechia |
| GRIMODIN | Latin | Czechia |
| Gabapentin Sandoz | Latin | Australia, Iceland |
| GASENLAN | Latin | Czechia |
| GABAPENTIN-WGR | Latin | Australia |
| GABAGAMMA | Latin | Czechia |
| Gabapentin APOTEX | Latin | Australia |
| GORDIUS | Latin | Czechia |
| Gabagen | Latin | Iceland |
| Gabanet | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
What is Gabapentin called in other languages?
Buyers, prescribers and procurement teams outside Canada often search for the ingredient in their own script. These are phonetic renderings of the ingredient name Gabapentin, published to help those searches reach this page.
| Language | Gabapentin |
|---|---|
| Russian Русский | Габапентин |
| Spanish Español | Gabapentina |
| French Français | Gabapentine |
| Portuguese Português | Gabapentina |
| German Deutsch | Gabapentin |
These are transliterations of the ingredient name, generated automatically and published only where two independent checks agreed. They are not registered local trade names and carry no marketing authorisation in any market. Always confirm a product against its local registration before ordering.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.